Therapy for patients with heparin-induced thrombocytopenia marketed.
D000925:Anticoagulants / Q000627:therapeutic use*; D017277:Drug Approval; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000009:adverse effects*; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy*; D013923:Thromboembolism / Q000517:prevention & control*; D014481:United States; D014486:United States Food and Drug Administration
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006629:Hirudins; D011994:Recombinant Proteins; D006493:Heparin; C083544:lepirudin